<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43425">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752725</url>
  </required_header>
  <id_info>
    <org_study_id>04122012</org_study_id>
    <nct_id>NCT01752725</nct_id>
  </id_info>
  <brief_title>Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)</brief_title>
  <official_title>Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH): A Prospective, Controlled, Randomized, Non-inferiority in Vivo Human Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ERBE Elektromedizin GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the evaluation of the efficiency and safety of the new, CE-certified
      thermofu-sion and dissection instrument BiCision® in comparison with the long established
      Ultracision® Har-monic Scalpel(Ethicon)during a  laparoscopic supracervical hysterectomy
      (LASH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Operation time</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expexted average of 8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is the operation time for each preparation side and instrument needed from the beginning of the removal of the cornual structure of the uterus (uterine cornu) till the completely removal of the parametric tissue directly before removal of the corpus uteri from the cervix.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Uterine Bleeding Disorders</condition>
  <condition>Benign Uterine Conditions</condition>
  <condition>Focus: Comparison of Two Instruments</condition>
  <arm_group>
    <arm_group_label>BiCision Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coagulation with BiCision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultracision Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coagulation with Ultracision</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiCision®</intervention_name>
    <arm_group_label>BiCision Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultracision® Har-monic Scalpel(Ethicon)</intervention_name>
    <arm_group_label>Ultracision Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18

          -  gender: female

          -  indication for laparoscopic supracervical hysterectomy with no adnexectomyor other
             surgery

          -  will and the capability to comply the study requirements

          -  signed informed consent

        Exclusion Criteria:

          -  Invasive malignome in the pelvis

          -  Cardiac pacemaker or implanted defibrilator if no informations are available about
             the compatibil-ity with RF energy

          -  Abnormal blood parameters (values less than factor 0.8 or more than 1.25 compared to
             the val-ues of creatinine and standard hemogram)

          -  Abnormal coagulation parameters: PTT &gt; 40 sec. and / or  Quick's-Value&lt; 50% (the use
             of antiplateletsup to a max. of 100mg/d is no exclusion criteria)

          -  Inability to understand the purpose of the study

          -  status after a laparotomy by a longitudinal incision

          -  intraabdominal adhesions (at the beginning of the surgery ≥ 5 sectioning for
             adhesiolysis)

          -  open laparoscopy required

          -  different anatomical situations that yields to different surgery requirements

          -  conspicuous  PAP, cervixmyoma or endometriosis of  the rectovaginale space
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diethelm Wallwiener, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard Krämer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 14, 2012</lastchanged_date>
  <firstreceived_date>December 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Bernhard Kraemer</investigator_full_name>
    <investigator_title>Executive / Investigator</investigator_title>
  </responsible_party>
  <keyword>supracervical hysterectomy</keyword>
  <keyword>vessel sealing</keyword>
  <keyword>bipolar electrocoagulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
